ArticleNature reviews. Materials2025
Next-generation materials for nucleic acid delivery.
Article in Nature reviews. Materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Advancing PROTAC therapeutics through chemistry-guided design of smart delivery systems.Acta pharmacologica Sinica · 2026Review
- Nano-antimicrobial peptides (Nano-AMPs) to combat resistant gram-negative bacteria.Drug delivery and translational research · 2026Review
- Direct Cytosolic Delivery of Amphiphilic Framework Nucleic Acids for RNA Interference.Angewandte Chemie (International ed. in English) · 2026Article
- Precision chemical engineering of dendrimers for nucleic acid delivery.Nature reviews. Chemistry · 2026Review
- Assembly delivery of bioactive matters: Advances, challenges, and prospects.Journal of advanced research · 2026Review
- Amine oxide lipid nanoparticles for delivery of cyclic dinucleotides.National science review · 2026Article
- Nanocarriers engineering for efficient NSUN2 silencing and immune responsive therapy in metastatic colorectal cancer.Materials today. Bio · 2026Article
- AIEgen-mediated integration of plain DNA and hydrophobic compounds enabling three-in-one nanosystems for carrier-free delivery.Journal of nanobiotechnology · 2026Article
- Lipid droplet dynamics in metabolic regulation.RSC chemical biology · 2026Review
- Controlled Delivery and Light-Induced Release of Magic Spot Nucleotides in Escherichia coli.Angewandte Chemie (International ed. in English) · 2026Article
- Article
- Functions and applications of enzymes in nucleic acid nanotechnology.Journal of nanobiotechnology · 2025Review
- Nanoparticle-based drug delivery systems: A promising approach for the treatment of liver fibrosis.International journal of pharmaceutics: X · 2025Review
- PEGylation Enhances Colloidal Stability and Promotes Ligand-Mediated Targeting of LAF-Xenopeptide mRNA Complexes.Polymers · 2025Article
- Transfection Technologies for Next-Generation Therapies.Journal of clinical medicine · 2025Review
- Ferroptosis-immune-metabolic axis in asthma: mechanistic crosstalk, endotype-specific regulation, and translational targeting.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Efficient and targeted delivery of nucleic acids is critical for realizing the full therapeutic potential of gene editing, vaccines and RNA-based drugs, and emerging delivery platforms offer innovative solutions through their diverse architectures, tunable properties and distinct biological interactions. In this Viewpoint, researchers working across different delivery platforms - including lipid nanoparticles, synthetic polymers, peptide amphiphiles, coacervate microdroplets, DNA nanostructures and extracellular vesicles - discuss the most promising directions and the main challenges in shaping the future of nucleic acid delivery.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.